Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease.

J Clin Transl Endocrinol · 2022 · PMC9816064 · PMID 36620756

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

marginally significantP = 0.08so close (0.05 < p ≤ 0.1)

For eGFR < 45 mL/min outcome, the association between use of SGLT-2 inhibitors and lower event rate of eGFR < 45 mL/min was marginally significant (P = 0.08).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.